

Innovative Strategies — TO TREAT — Schizophrenia



Industry Satellite Symposium

Saturday, September 12, 2020 17:30 - 19:00

Room 1

Session: ISS.03

Industry Satellite Symposium on the occasion of the 33rd ECNP Congress with educational financial support provided by Sunovion and Sumitomo Dainippon Pharma/Global Medical Education. This Industry Satellite Symposium is open to all attendees of the 33rd ECNP Congress. This session offers 2 CME credits.

Schizophrenia is a leading cause of disability and premature mortality in the world. There are major unmet needs in schizophrenia that are not addressed by current antipsychotic treatments. Moreover, antipsychotic drugs are ineffective or not tolerated in two thirds of patients with schizophrenia. This symposium aims to consider the challenges facing the field, and provide a cutting-edge update on the latest developments in the treatment of schizophrenia informed by advances in understanding the neurobiology underlying the disorder.

C·M·E



C·N·S
EUROPEAN
ACCREDITATION
COMMITTEE

The European Accreditation Committee in CNS (EACIC) has granted 2 CME credits to this Industry Satellite Symposium. To receive a certificate of CME credits, please complete the evaluation form that will be made available directly from the 33rd ECNP Congress Virtual. Deadline: 15 December 2020

This activity is supported by an independent educational grant from Sunovion and Sumitomo Dainippon Pharma

Program Agenda

17:30 - 17:35 *Opening Remarks by Chair*

17:35 - 17:55 *Unmet Needs in the Treatment of Schizophrenia*

INGRID MELLE MD, UNIVERSITY OF OSLO

17:55 - 18:15 *Innovative Targets for Drug Discovery for Schizophrenia*

RACHEL UPTHEGROVE MBBS FRCPsych
PhD, UNIV OF BIRMINGHAM

18:15 - 18:35 *Current and Emerging Treatments for Schizophrenia*

OLIVER HOWES MD, KINGS COLLEGE
LONDON, CHAIR

18:35 - 18:55 *Q&A*

18:55 - 19:00 *Closing Remarks*



GLOBAL MEDICAL
EDUCATION

Global Medical Education
26 East 63rd Street
New York, NY 10065
info@gmeded.com

